FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. PMID 38768714 · Radiother Oncol · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). PMID 38767786 · Breast Cancer Res Treat · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Step by step technique of Stentless Florence Robotic Intracorporeal Neobladder (FloRIN), does the ureteral management influence functional outcomes? PMID 38752506 · Urologia · 2024-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial. PMID 38747213 · Diabetes Obes Metab · 2024-Aug The study is a secondary, exploratory analysis of a large randomized trial (ORIGIN) in prediabetes/type 2 diabetes. While it involves a drug intervention (glargine) and is human and randomized, it is not an oncology-focused study. The reported outcome is a composite of serious health events (including cancer), not a standard time-to-event efficacy endpoint for an oncology drug. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial. PMID 38747163 · ACR Open Rheumatol · 2024-Aug The study is a Phase 3 randomized trial of upadacitinib for non-radiographic axial spondyloarthritis, a rheumatic disease. It is not an oncology study of human malignant neoplasm. Furthermore, the efficacy endpoints reported are not time-to-event outcomes (e.g., no OS, PFS, DFS, etc.) and do not involve Kaplan-Meier analysis or hazard ratios for such endpoints. Therefore, it does not meet the eligibility criteria for the cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stapler versus conventional pharyngeal repair after total laryngectomy: a randomized clinical trial. PMID 38739184 · Eur Arch Otorhinolaryngol · 2024-Aug The record describes a randomized surgical technique comparison trial without a drug intervention, and the trial phase is not confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Screening optimal candidates with operable, early-stage triple-negative breast cancer benefitting from capecitabine maintenance: A post-hoc analysis of the SYSUCC-001 study. PMID 38733700 · Breast · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. PMID 38726639 · Eur J Neurol · 2024-Aug 未发现恶性肿瘤人群证据。 |
H
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer. PMID 38725182 · BJU Int · 2024-Aug The study is a retrospective subgroup analysis of a randomized screening trial, not a drug intervention trial. It lacks a Phase III/IIIb or Phase II/III drug trial designation and does not involve a drug-containing intervention arm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a self-determination theory-based smoking cessation intervention plus instant messaging via mobile application for smokers with cancer: Protocol for a pragmatic randomized controlled trial. PMID 38708618 · Addiction · 2024-Aug 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. PMID 38704501 · Ann Surg Oncol · 2024-Aug The record is an original result report of a Phase III oncology study with drug intervention and time-to-event endpoints (OS, PFS). However, it is explicitly described as a 'single-arm' study, which does not meet the required criterion of a randomized trial for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of intraoperative low-dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double-blind, placebo-controlled study. PMID 38657619 · Br J Clin Pharmacol · 2024-Aug 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. PMID 38648896 · Clin Microbiol Infect · 2024-Aug Study is a randomized trial in an oncology population but does not meet key eligibility criteria: it lacks a drug-containing oncology intervention (focus is on antibiotic stewardship) and does not report time-to-event efficacy endpoints (Kaplan-Meier, HR, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial. PMID 38635062 · Heart Vessels · 2024-Aug The record describes a randomized, controlled trial in a non-oncology setting (cardiology). The primary efficacy endpoints are not time-to-event endpoints (OS, PFS, etc.), and the trial phase is not confirmed as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. PMID 38570034 · J Hepatol · 2024-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). PMID 38451052 · J Eur Acad Dermatol Venereol · 2024-Aug The record is a safety analysis of a phase 3 trial in plaque psoriasis, a non-oncology condition. It does not report a time-to-event efficacy endpoint for a human malignant neoplasm. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of two 3D reconstruction models for understanding of complicated female pelvic tumors. PMID 38425240 · Int J Gynaecol Obstet · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Individualized Homeopathic Medicines in the Treatment of Hemorrhoids: Double-Blind, Randomized, Placebo-Controlled Trial. PMID 38301138 · J Integr Complement Med · 2024-Aug This is a randomized, double-blind, placebo-controlled trial of individualized homeopathic medicines for hemorrhoids, not a human malignant neoplasm. The primary and secondary endpoints are patient-reported outcome measures (symptom severity and quality-of-life questionnaires), not time-to-event endpoints like OS, PFS, DFS, or similar. The intervention is homeopathic, not a standard oncologic drug. Therefore, it fails the core criteria of oncology, drug intervention, and time-to-event endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. PMID 38072759 · Eur Urol Oncol · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6:508-515. PMID 37872030 · Eur Urol Oncol · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6:508-515. PMID 37865570 · Eur Urol Oncol · 2024-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. PMID 37858437 · Eur Urol Oncol · 2024-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life. PMID 37690917 · Eur Urol Oncol · 2024-Aug The study is a randomized oncology trial but does not meet the key inclusion criteria: it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) reported with Kaplan-Meier or HR. The focus is on screening outcomes, not therapeutic efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01). PMID 38660276 · Heliyon · 2024-Apr-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. PMID 38688309 · J Natl Compr Canc Netw · 2024-Apr-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Effectiveness of Perioperative Hyperthermic Intraperitoneal Chemotherapy with Gemcitabine in Patients with Resected Pancreatic Ductal Adenocarcinoma: Clinical Trial EudraCT 2016-004298-41. PMID 38730669 · Cancers (Basel) · 2024-Apr-28 Eligibility criteria require explicit Phase III/IIIb or Phase II/III evidence. The record provides a EudraCT number but does not state the trial phase. Without explicit phase information, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lidocaine effects on neutrophil extracellular trapping and angiogenesis biomarkers in postoperative breast cancer patients with different anesthesia methods: a prospective, randomized trial. PMID 38678209 · BMC Anesthesiol · 2024-Apr-27 The study is a randomized, controlled trial in human breast cancer patients evaluating drug interventions (lidocaine with different anesthesia regimens). However, it lacks any report of a Phase III/IIIb or Phase II/III designation, and its primary endpoint is biomarker-based (serum concentrations of NETosis and angiogenesis markers), not a clinical time-to-event outcome (like OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. PMID 38582092 · Lancet · 2024-Apr-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Community Health workers United to Reduce Colorectal cancer and cardiovascular disease among people at Higher risk (CHURCH): study protocol for a randomized controlled trial. PMID 38671470 · Trials · 2024-Apr-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis. PMID 38659013 · Cost Eff Resour Alloc · 2024-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of a single subanesthetic dose of esketamine on postoperative subthreshold depressive symptoms in patients undergoing unilateral modified radical mastectomy: a randomised, controlled, double-blind trial. PMID 38658886 · BMC Psychiatry · 2024-Apr-24 The study is a randomized trial in breast cancer patients evaluating a drug (esketamine) with an original primary outcome (PHQ-9 score), which is not a time-to-event endpoint. The phase is not specified as Phase III or definitive. Therefore, it does not meet all eligibility criteria for the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Role of neoadjuvant rectal score in prognosis and adjuvant chemotherapy decision-making in locally advanced rectal cancer following neoadjuvant short-course radiotherapy and consolidation chemotherapy]. PMID 38644269 · Zhonghua Zhong Liu Za Zhi · 2024-Apr-23 This is a secondary analysis of the STELLAR Phase III trial, focusing on the prognostic value of the NAR score and its role in guiding adjuvant chemotherapy decisions. It is not the primary, formal report of the trial's randomized intervention comparison. The randomization status of the underlying trial is not explicitly confirmed in this record, and the analysis itself is a biomarker/prognostic subgroup study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. PMID 37801628 · J Crohns Colitis · 2024-Apr-23 The record describes a study in ulcerative colitis and Crohn's disease (inflammatory bowel disease), which is not a human malignant neoplasm. Furthermore, the primary endpoints are clinical/endoscopic response and remission at fixed time points (Week 8/52/12/56), not time-to-event outcomes like overall survival or progression-free survival analyzed with Kaplan-Meier or hazard ratios. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The TELEhealth Shared decision-making Coaching and Navigation in Primary carE (TELESCOPE) intervention: a study protocol for delivering shared decision-making for lung cancer screening by patient navigators. PMID 38746205 · Res Sq · 2024-Apr-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial. PMID 38215354 · J Clin Oncol · 2024-Apr-20 The study is a randomized, double-blind, placebo-controlled trial with primary results and a time-to-event endpoint (hazard ratio for time to develop severe oral mucositis). However, the intervention is a probiotic lozenge (Streptococcus salivarius K12), which is not a pharmacologic drug. Therefore, it does not meet the drug-intervention criterion required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum. PMID 38641834 · J Ovarian Res · 2024-Apr-19 The record describes a randomized surgical trial for epithelial ovarian cancer with a primary time-to-event endpoint (progression-free survival). However, it fails two key eligibility criteria: 1) The intervention is surgical only, with no drug component (e.g., chemotherapy) described in the abstract, and 2) the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, making it ineligible for this digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. PMID 38637770 · BMC Cancer · 2024-Apr-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. PMID 38226713 · Br J Dermatol · 2024-Apr-17 Study evaluates deucravacitinib in plaque psoriasis, which is not a human malignant neoplasm (oncology). While it meets criteria for human, randomized, phase III, drug intervention, and original results, the non-oncology disease category excludes it from this cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A new midline closure technique without skin sutures: Long-term outcomes of primary repair of pilonidal sinus disease. PMID 38725367 · An Sist Sanit Navar · 2024-Apr-16 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enhancing diagnosis of benign lesions and lung cancer through ensemble text and breath analysis: a retrospective cohort study. PMID 38627587 · Sci Rep · 2024-Apr-16 The study is a retrospective cohort study for diagnostic model development, not a randomized trial evaluating a drug intervention with a time-to-event efficacy endpoint. It lacks drug intervention, Phase III designation, and any time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. PMID 38406848 · Circulation · 2024-Apr-16 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers. PMID 38660631 · World J Gastrointest Oncol · 2024-Apr-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial. PMID 38593249 · Clin Cancer Res · 2024-Apr-15 The record is a Phase IIb randomized trial with oncology, human, and drug intervention criteria met, and it reports a primary time-to-event endpoint (PFS). However, it does not meet the 'phase3_or_definitive' criterion, which requires explicit evidence of a Phase III/IIIb or Phase II/III trial. The title and abstract explicitly state it is a Phase IIb trial, which is insufficient for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. PMID 38127487 · Cancer · 2024-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Thromboxane biosynthesis and future events in diabetes: the ASCEND trial. PMID 38385506 · Eur Heart J · 2024-Apr-14 This is a secondary biomarker analysis from the ASCEND trial, which is a randomized, placebo-controlled trial in humans with diabetes. While the trial is oncology-eligible (cancer is a secondary endpoint), this specific report does not present primary or key secondary efficacy results for the drug intervention. The drug intervention (aspirin) is part of the trial, but this publication focuses on the association of urinary thromboxane with outcomes, not the primary trial efficacy. The trial phase is not explicitly stated in the metadata. Therefore, it is not eligible as an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Melanoma neoantigen vaccines: Are we getting more personal now? PMID 38614074 · Med · 2024-Apr-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial. PMID 38228361 · Ann Rheum Dis · 2024-Apr-11 The study is a randomized controlled trial of a drug-containing intervention (celecoxib + golimumab vs. golimumab) with a primary endpoint of radiographic spinal progression (mSASSS change) in axial spondyloarthritis, which is not a malignancy and does not involve a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It is excluded for being non-oncology and lacking the required time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ultrasound-guided stellate ganglion block benefits the postoperative recovery of patients undergoing laparoscopic colorectal surgery: a single-center, double-blinded, randomized controlled clinical trial. PMID 38600490 · BMC Anesthesiol · 2024-Apr-10 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters. PMID 38594766 · Trials · 2024-Apr-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. PMID 38301187 · J Clin Oncol · 2024-Apr-10 This is a Phase III randomized trial of olaparib in early breast cancer, but the reported results focus exclusively on patient-reported outcomes (fatigue, nausea/vomiting, quality of life) and not on time-to-event efficacy endpoints like OS or PFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |